ReviewAnnals of clinical microbiology and antimicrobials2021
An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.
Review in Annals of clinical microbiology and antimicrobials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Metagenomic Characterisation of Antibiotic Resistance in Anaerobic Digesters and Their Implications for Environmental Health.Environmental microbiology reports · 2026Article
- Vaginal microbiomes and their pertinent social context: a microbial ecological review proffering AMR-STI acquisition and emergence.Biology of sex differences · 2026Review
- Epidemiological shifts and clinical characteristics of childhood Chlamydia pneumoniae pneumonia in Beijing before, during, and after public health interventions (2017-2025).BMC infectious diseases · 2026Article
- Observational
- Putative azithromycin resistance mutations inAntimicrobial agents and chemotherapy · 2026Article
- A Nationwide Investigation on the Distribution and Antimicrobial Susceptibility Profiling ofInfection & chemotherapy · 2026Article
- Anti-International journal of molecular sciences · 2026Review
- Clinical management and pharmaceutical care of severeFrontiers in cellular and infection microbiology · 2026Review
- Antimicrobial Management of SevereInfection and drug resistance · 2026Review
- Gut microbial alterations associated with the exacerbation of experimental autoimmune uveitis in PGRN-deficient mice.Frontiers in immunology · 2026Article
- Kaempferol inhibitsFrontiers in microbiology · 2026Article
- Phylogenetic relationships and antimicrobial susceptibility of human- and parrot-derivedFrontiers in cellular and infection microbiology · 2026Article
- Azithromycin alters the microbiome composition, function and resistome in women with Chlamydia trachomatis infections.NPJ biofilms and microbiomes · 2025Article
- Evolutionary dynamics in the genome of ocularMicrobial genomics · 2025Article
- Leveraging the microbiome to combat antibiotic resistant gynecological infections.npj antimicrobials and resistance · 2025Review
- Adoption of an in-silico analysis approach to assess the functional and structural impacts of rpoB-encoded protein mutations on Chlamydia pneumoniae sensitivity to antibiotics.BMC microbiology · 2025Article
- An Atypical Pneumonia Case of Quinolone-RefractoryInfection and drug resistance · 2025Article
- From Cure to Prevention: Doxycycline's Potential in Prophylaxis for Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Insights into the Two Most Common Cancers of Primitive Gut-Derived Structures and Their Microbial Connections.Medicina (Kaunas, Lithuania) · 2024Review
- Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects.npj antimicrobials and resistance · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChlamydiae are intracellular bacteria that cause various severe diseases in humans and animals. The common treatment for chlamydia infections are antibiotics. However, when antibiotics are misused (overuse or self-medication), this may lead to resistance of a number of chlamydia species, causing a real public health problem worldwide. MATERIALS AND
methodsIn the present work, a comprehensive literature search was conducted in the following databases: PubMed, Google Scholar, Cochrane Library, Science direct and Web of Science. The primary purpose is to analyse a set of data describing the genes and mutations involved in Chlamydiae resistance to antibiotic mechanisms. In addition, we proceeded to a filtration process among 704 retrieved articles, then finished by focusing on 24 studies to extract data that met our requirements.
resultsThe present study revealed that Chlamydia trachomatis may develop resistance to macrolides via mutations in the 23S rRNA, rplD, rplV genes, to rifamycins via mutations in the rpoB gene, to fluoroquinolones via mutations in the gyrA, parC and ygeD genes, to tetracyclines via mutations in the rpoB gene, to fosfomycin via mutations in the murA gene, to MDQA via mutations in the secY gene. Whereas, Chlamydia pneumoniae may develop resistance to rifamycins via mutations in the rpoB gene, to fluoroquinolones via mutations in the gyrA gene. Furthermore, the extracted data revealed that Chlamydia psittaci may develop resistance to aminoglycosides via mutations in the 16S rRNA and rpoB genes, to macrolides via mutations in the 23S rRNA gene. Moreover, Chlamydia suis can become resistance to tetracyclines via mutations in the tet(C) gene. In addition, Chlamydia caviae may develop resistance to macrolides via variations in the 23S rRNA gene. The associated mechanisms of resistance are generally: the inhibition of bacteria's protein synthesis, the inhibition of bacterial enzymes' action and the inhibition of bacterial transcription process.
conclusionThis literature review revealed the existence of diverse mutations associated with resistance to antibiotics using molecular tools and targeting chlamydia species' genes. Furthermore, these mutations were shown to be associated with different mechanisms that led to resistance. In that regards, more mutations and information can be shown by a deep investigation using the whole genome sequencing. Certainly, this can help improving to handle chlamydia infections and healthcare improvement by decreasing diseases complications and medical costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.